Fenwick Represents Until Labs in $58M Series A Funding

Fenwick represented Until Labs, a pioneering biotech company developing cutting-edge organ cryopreservation technology to extend the viability of donor organs and ultimately enable whole-body medical hibernation, in its $58M Series A funding. The funding round was led by Founders Fund with participation from Lux and Field Ventures.

Until will use the funds to further grow their team and to advance development of its reversible cryopreservation product, helping transplant patients and surgeons access life-saving organs more reliably and overcoming the current time and logistics limits in organ transplantation. Additional information can be obtained here.

The Fenwick transaction team was led by corporate partners Steven Levine and Will Black and included associates Anja Kong and Kale Olmstead.